Clinical Trials Browser

Terminated × dostarlimab × Plasma cell × Clear all

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Multiple Myeloma